|Mr. See Wah Lim||Exec. Chairman & CEO||N/A||N/A||1968|
|Ms. Lee Wei Fang||Chief Financial Officer||N/A||N/A||1976|
|Mr. Yann Alain Marche||Chief Operating Officer||N/A||N/A||N/A|
|Ms. Foong Jen Tang||Admin. Mang.||N/A||N/A||N/A|
|Mr. Chwee Choon Tan||Exec. Director & Regional Director of Indochina||N/A||N/A||1957|
|Ms. Stella Ang||Head of Regulatory Affairs||N/A||N/A||N/A|
|Ms. Loh Shaoli||Country Head of Philippines||N/A||N/A||N/A|
|Mr. Jamal Iflizar||Country Head of Indonesia||N/A||N/A||N/A|
|Mr. Ang Francis||Country Head of Malaysia||N/A||N/A||N/A|
|Ms. Sher Mei Lim C.A.||Company Sec.||N/A||N/A||N/A|
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, the Philippines, Indonesia, and Malaysia. The company's Specialty Pharma Principals segment sells and markets specialty pharmaceutical products, including StÃ©rimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup, Lidose, and Piascledine through distributorship or licensing, and supply agreements. This segment offers products in various therapeutic areas or medical specialties, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedic and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, and family medicine. Its Proprietary Brands segment develops, markets, and sells dermatological products and health supplement products. It offers dermocosmetic products under the Ceradan and TDF brands through medical professionals, such as general practitioners, dermatologists, pediatricians, and pharmacists; health supplement products under the Ocean Health brand directly to consumers via retail channels; and scalp care products under the CG 210 brand. The company's Medical Hypermart and Digital segment engages in the wholesale of pharmaceuticals and medical supplies for healthcare professionals and institutions, and retail pharmacies through tele-sales and sales representatives. This segment also operates an online B2B platform. It also markets and distributes its products in Bangladesh, Brunei, Cambodia, China, Hong Kong, Macau, Myanmar, Oman, Sri Lanka, and South Korea. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. It was founded in 1998 and is headquartered in Singapore. Hyphens Pharma International Limited is a subsidiary of Inomed Holding Pte Ltd.
Hyphens Pharma International Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.